Ibrahim Celalettin Haznedaroglu
Overview
Explore the profile of Ibrahim Celalettin Haznedaroglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haznedaroglu I, Malkan U
Adv Exp Med Biol
. 2024 Sep;
1460:575-594.
PMID: 39287865
Lipotoxicity can mediate endothelial dysfunction in obesity. Altered endothelial cell phenotype during the pathobiological course of the lipotoxicity may lead to hemostatic abnormalities, which is a hallmark of several hematological...
2.
Senel E, Turk S, Malkan U, Peker M, Turk C, Guner H, et al.
Turk J Med Sci
. 2024 May;
53(5):1194-1204.
PMID: 38813031
Background/aim: The clinical presentation of pediatric coronavirus disease 2019 (COVID-19) is associated with a milder disease course than the adult COVID-19 syndrome. The disease course of COVID-19 has three clinicobiological...
3.
Turk S, Yanpar H, Baesmat A, Demirkol Canli S, Cinar O, Malkan U, et al.
Heliyon
. 2023 Oct;
9(9):e19743.
PMID: 37810000
As in the case of cancer, the risk of infection increases when the host's immune system is not working properly. It has been shown that toxins produced by the bacteria...
4.
Karacan Y, Yildiz H, Evrensel T, Haznedaroglu I
Support Care Cancer
. 2023 Jun;
31(7):385.
PMID: 37289263
Introduction: New agents are introduced each day to be used in the prevention and treatment of mucositis in cancer treatment. One of those agents is the Ankaferd hemostat. Ankaferd hemostat...
5.
A single-center experience of haploidentical stem cell transplantation in hematological malignancies
Malkan U, Goker H, Demiroglu H, Tekin F, Akdemir N, Aladag Karakulak E, et al.
Turk J Med Sci
. 2023 Mar;
53(1):352-359.
PMID: 36945951
Background: Since well-designed prospective comparative trials are lacking, haploidentical hematopoietic stem cell transplantations approach should be based on the expertise of a particular center. In this study, we aimed to...
6.
Cinar O, Erdogdu B, Karadeniz M, Unal S, Malkan U, Goker H, et al.
Medicina (Kaunas)
. 2022 Nov;
58(11).
PMID: 36363532
The SARS-CoV-2 spike protein mRNA-based vaccines have prevented countless mortality and morbidity, and have an excellent risk/benefit ratio. However, various adverse events may rarely occur after the BNT162b2 vaccine, like...
7.
Canbaz H, Idiz U, Dal H, Kaciroglu F, Tas S, Cubukcu H, et al.
Turk J Haematol
. 2022 Oct;
39(4):222-229.
PMID: 36250478
Objective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the...
8.
Turk S, Baesmat A, Yilmaz A, Turk C, Malkan U, Ucar G, et al.
Open Med (Wars)
. 2022 Oct;
17(1):1495-1506.
PMID: 36213442
Acute myeloid leukemia (AML) is the most heterogeneous hematological disorder and blast cells need to fight against immune system. Natural killer (NK) cells can elicit fast anti-tumor responses in response...
9.
Karatas A, Goker H, Demiroglu H, Malkan U, Velet M, Cinar O, et al.
Turk J Med Sci
. 2022 Sep;
52(2):413-419.
PMID: 36161632
Background: Thrombocytopenia is a common complication following hematopoietic stem cell transplantation (HSCT). Eltrombopag has been used in thrombocytopenia treatment after HSCT in recent years. Herein, we present our experience of...
10.
Saydam G, Unal A, Haznedaroglu I, Hacihanifioglu A, Mehtap O, Kurtoglu E, et al.
Int J Hematol Oncol
. 2022 Sep;
11(3):IJH40.
PMID: 36101779
Aim: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML)...